SIDNEY CARLTON GORTON
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- BELZONI, MS
- NPI
- 1972572683
- Received
- $7,054 in 235 records, 2019 to 2025
- As principal investigator
- $564,224 of research payments to others in 87 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 22 | $588 |
| 2024 | General payment | 20 | $373 |
| 2023 | General payment | 19 | $1,783 |
| 2022 | General payment | 38 | $858 |
| 2021 | General payment | 48 | $752 |
| 2020 | General payment | 53 | $2,123 |
| 2019 | General payment | 35 | $575 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $1,344 | 2019–2023 |
| Novo Nordisk Inc | 63 | $1,280 | 2019–2025 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $1,247 | 2020–2022 |
| AstraZeneca Pharmaceuticals LP | 25 | $976 | 2019–2025 |
| Janssen Pharmaceuticals, Inc | 29 | $431 | 2019–2022 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 22 | $335 | 2019–2025 |
| Lilly USA, LLC | 13 | $242 | 2020–2024 |
| Lundbeck LLC | 10 | $208 | 2023–2025 |
| Merck Sharp & Dohme LLC | 9 | $195 | 2020–2023 |
| GlaxoSmithKline, LLC. | 10 | $155 | 2019–2025 |
| PFIZER INC. | 8 | $108 | 2019–2024 |
| SANOFI-AVENTIS U.S. LLC | 6 | $84 | 2019–2023 |
| Amarin Pharma, Inc. | 5 | $72 | 2020–2021 |
| Abbott Laboratories | 4 | $71 | 2021–2025 |
| Amgen Inc. | 3 | $52 | 2020–2025 |
| ABBVIE INC. | 3 | $47 | 2019–2023 |
| Mylan Specialty L.P. | 2 | $40 | 2020–2021 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 | 2023 |
| Verona Pharma, Inc. | 1 | $30 | 2025 |
| Insulet Corporation | 1 | $27 | 2024 |
| Esperion Therapeutics, Inc. | 1 | $22 | 2025 |
| SANOFI PASTEUR INC. | 1 | $17 | 2020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 | 2019 |
| Astellas Pharma US Inc | 1 | $14 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Food and Beverage | 230 | $4,851 |
| Consulting Fee | 1 | $1,158 |
| Travel and Lodging | 3 | $1,031 |
| Education | 1 | $13 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-10 | AstraZeneca Pharmaceuticals LP | $1 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-11-17 | Lundbeck LLC | $27 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-14 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-09-24 | Lundbeck LLC | $20 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-15 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-07 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-08-01 | Esperion Therapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-07-22 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-13 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-09 | AstraZeneca Pharmaceuticals LP | $107 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-16 | Novo Nordisk Inc | $125 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-04-11 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-04-09 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-03-17 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-03-07 | Verona Pharma, Inc. | $30 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-02-25 | Lundbeck LLC | $20 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-02-13 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2025 | |
| 2025-02-12 | Novo Nordisk Inc | $6 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-01-23 | Abbott Laboratories | $13 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-01-10 | Lundbeck LLC | $18 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2024-12-12 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-12-03 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-11-20 | Lundbeck LLC | $18 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-10-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage (2 payments) | In-kind items and services | 2024 | ||
| 2024-10-25 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-10-22 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-10-10 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-09-27 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-09-05 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-08-27 | Insulet Corporation | $27 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-08-16 | Lundbeck LLC | $15 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-08-09 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | AREXVY Drug, RESPIRATORY | 2024 | |
| 2024-08-06 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-07-30 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | OXBRYTA Drug, HEMATOLOGY | 2024 | |
| 2024-07-26 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-06-28 | Lundbeck LLC | $25 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-06-20 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-06-15 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-02-27 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-02-02 | Lundbeck LLC | $16 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2023-11-02 | Otsuka America Pharmaceutical, Inc. | $31 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-10-25 | AstraZeneca Pharmaceuticals LP | $105 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-10-19 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-09-29 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-09-26 | Merck Sharp & Dohme LLC | $93 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-09-15 | Lundbeck LLC | $29 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-09-15 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-30 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2023 | |
| 2023-06-08 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-06-01 | AstraZeneca Pharmaceuticals LP | $100 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-05-23 | SANOFI-AVENTIS U.S. LLC | $17 | Food and Beverage | In-kind items and services | TOUJEO Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-05-17 | Lundbeck LLC | $17 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-03-24 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $468 | Travel and Lodging | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $442 | Travel and Lodging | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $223 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-03-11 | Novartis Pharmaceuticals Corporation | $120 | Travel and Lodging | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-01-27 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | STEGLATRO Drug, ENDOCRINOLOGY | 2023 | |
| 2022-12-23 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-12-13 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-12-06 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-12-01 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-11-17 | SANOFI-AVENTIS U.S. LLC | $13 | Food and Beverage | In-kind items and services | TOUJEO Biological, Endocrine & Metabolic Diseases | 2022 | |
| 2022-11-07 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-10-31 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-10-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-09-27 | AstraZeneca Pharmaceuticals LP | $123 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2022 | |
| 2022-09-18 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2022 | |
| 2022-08-30 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-08-23 | Lilly USA, LLC | $67 | Food and Beverage | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-08-23 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-08-18 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-08-02 | Novo Nordisk Inc | $121 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-07-25 | Novo Nordisk Inc | $5 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-07-22 | Bayer Healthcare Pharmaceuticals Inc. | $12 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-07-14 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-07-13 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-07-08 | Merck Sharp & Dohme LLC | $11 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2022 | |
| 2022-06-24 | Novo Nordisk Inc | $4 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-06-16 | Janssen Pharmaceuticals, Inc | $19 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-06-06 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-05-12 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-05-10 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-05-10 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2022 | |
| 2022-05-03 | Novo Nordisk Inc | $3 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-04-13 | Novo Nordisk Inc | $3 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-04-07 | Novo Nordisk Inc | $125 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-03-24 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-03-24 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2022 | |
| 2022-03-11 | Novo Nordisk Inc | $3 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-03-03 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-03-01 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2022 | |
| 2022-02-14 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-02-02 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-01-24 | Novo Nordisk Inc | $1 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-01-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2021-12-13 | Bayer Healthcare Pharmaceuticals Inc. | $12 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-12-09 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-12-09 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-12-03 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-12-01 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-11-24 | Novo Nordisk Inc | $1 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-11-23 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | 2021 | |
| 2021-11-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-11-12 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-11-05 | Novo Nordisk Inc | $1 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-10-26 | Janssen Pharmaceuticals, Inc | $13 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-10-08 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-09-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-09-20 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-09-17 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-08-31 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-08-16 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-08-06 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-08-06 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Education | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-07-29 | Janssen Pharmaceuticals, Inc | $13 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-06-24 | Amarin Pharma, Inc. | $17 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-06-24 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-06-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-06-10 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-06-03 | Novo Nordisk Inc | $105 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-06-03 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | PREMARIN Drug, WOMENS HEALTH | 2021 | |
| 2021-05-20 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-05-18 | Mylan Specialty L.P. | $19 | Food and Beverage | In-kind items and services | Yupelri Drug, Anticholinergics, Inhaled | 2021 | |
| 2021-05-11 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-05-07 | Amarin Pharma, Inc. | $14 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-05-07 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2021 | |
| 2021-04-15 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-04-07 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2021 | |
| 2021-04-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-03-31 | SANOFI-AVENTIS U.S. LLC | $11 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2021 | |
| 2021-03-26 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | PREMARIN Drug, WOMENS HEALTH | 2021 | |
| 2021-03-12 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-03-02 | Janssen Pharmaceuticals, Inc | $13 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-02-26 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2021 | |
| 2021-02-09 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-02-03 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-01-29 | Amarin Pharma, Inc. | $15 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-01-27 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2021 | |
| 2021-01-21 | Merck Sharp & Dohme LLC | $11 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2021 | |
| 2021-01-20 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-01-19 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-01-11 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2020-12-21 | Amarin Pharma, Inc. | $13 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $11 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2020 | |
| 2020-11-26 | Janssen Pharmaceuticals, Inc | $13 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-11-13 | Novo Nordisk Inc | $5 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-11-09 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2020 | |
| 2020-10-30 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-10-29 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-10-23 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-10-20 | Novo Nordisk Inc | $1 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-10-16 | Janssen Pharmaceuticals, Inc | $19 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-10-14 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | BREZTRI AEROSPHERE Drug, Respiratory | 2020 | |
| 2020-10-08 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-10-07 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | BASAGLAR Drug, Diabetes | 2020 | |
| 2020-10-01 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | BREZTRI AEROSPHERE Drug, Respiratory | 2020 | |
| 2020-09-24 | Merck Sharp & Dohme LLC | $11 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2020 | |
| 2020-09-15 | Mylan Specialty L.P. | $20 | Food and Beverage | In-kind items and services | Yupelri Drug, Respiratory and Allergy | 2020 | |
| 2020-09-11 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-09-04 | Novo Nordisk Inc | $3 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-09-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | TRADJENTA Drug, DIABETES | 2020 | |
| 2020-08-29 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-08-28 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-08-27 | Bayer Healthcare Pharmaceuticals Inc. | $1,158 | Consulting Fee | Cash or cash equivalent | Non-Covered | 2020 | |
| 2020-08-27 | Amarin Pharma, Inc. | $11 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-08-24 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2020 | |
| 2020-08-13 | AstraZeneca Pharmaceuticals LP | $120 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-08-07 | Merck Sharp & Dohme LLC | $11 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2020 | |
| 2020-08-04 | Janssen Pharmaceuticals, Inc | $19 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-07-31 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2020 | |
| 2020-07-28 | Novo Nordisk Inc | $86 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2020 | |
| 2020-07-23 | Astellas Pharma US Inc | $14 | Food and Beverage | In-kind items and services | MYRBETRIQ Drug, UROLOGY | 2020 | |
| 2020-07-22 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2020 | |
| 2020-07-20 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | COLOGUARD Device, GASTROINTESTINAL | 2020 | |
| 2020-07-16 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | CHANTIX Drug, NEUROSCIENCE;TOBACCO DEPENDENCE | 2020 | |
| 2020-07-14 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-06-25 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage (2 payments) | In-kind items and services | SYMBICORT Drug, Respiratory | 2020 | |
| 2020-06-22 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-06-19 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-06-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2020 | |
| 2020-06-02 | Novo Nordisk Inc | $1 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-05-28 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-05-14 | Janssen Pharmaceuticals, Inc | $19 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2020 | |
| 2020-04-29 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-04-28 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-04-24 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-04-14 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-02-20 | SANOFI PASTEUR INC. | $17 | Food and Beverage | In-kind items and services | FLUZONE HIGH-DOSE Biological, Vaccines | 2020 | |
| 2020-02-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2020 | |
| 2020-02-07 | Novo Nordisk Inc | $3 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-01-29 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | LYRICA Drug, NEUROSCIENCE;PAIN | 2020 | |
| 2020-01-28 | SANOFI-AVENTIS U.S. LLC | $11 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrinology | 2020 | |
| 2020-01-14 | Janssen Pharmaceuticals, Inc | $13 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 |
The latest 200 records of 235.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-17 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $90 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-10-23 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $2,000 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With P | 2025 |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $45,386 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $21,061 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2024-02-27 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $7,962 | EX9536-4388 | 2024 |
| 2024-01-30 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $44,459 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-01-15 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $30,874 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2024 |
| 2023-08-18 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,179 | EX9536-4388 | 2023 |
| 2023-07-26 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $550 | EX9536-4388 | 2023 |
| 2023-06-23 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $765 | EX9536-4388 | 2023 |
| 2023-05-26 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,530 | EX9536-4388 | 2023 |
| 2023-05-12 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $20 | EX9536-4388 | 2023 |
| 2023-04-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,482 | EX9536-4388 | 2023 |
| 2023-03-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,158 | EX9536-4388 | 2023 |
| 2023-03-16 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $85 | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and T | 2023 |
| 2023-02-22 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $315 | EX9536-4388 | 2023 |
| 2023-02-07 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $56,610 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-01-26 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $24,199 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-01-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,322 | EX9536-4388 | 2023 |
| 2023-01-23 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $5 | EX9536-4388 | 2023 |
| 2023-01-15 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $22,800 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2023 |
| 2022-12-21 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $637 | EX9536-4388 | 2022 |
| 2022-10-21 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,231 | EX9536-4388 | 2022 |
| 2022-10-18 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $5,993 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, 20-WEEK DOSE-FINDING STUDY TO EVALUATE EFFICACY, SAFETY, AND T | 2022 |
| 2022-07-27 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,231 | EX9536-4388 | 2022 |
| 2022-06-29 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,188 | EX9536-4388 | 2022 |
| 2022-06-14 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $1,681 | MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEV | 2022 |
| 2022-04-29 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $888 | EX9536-4388 | 2022 |
| 2022-03-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,113 | EX9536-4388 | 2022 |
| 2022-02-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $270 | EX9536-4388 | 2022 |
| 2022-02-09 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,301 | EX9536-4388 | 2022 |
| 2022-01-20 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $75 | EX9536-4388 | 2022 |
| 2022-01-15 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $34,518 | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2022 |
| 2022-01-12 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $83,148 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CAR | 2022 |
| 2022-01-10 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $8 | EX9536-4388 | 2022 |
| 2021-12-22 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,188 | EX9536-4388 | 2021 |
| 2021-12-14 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $2,000 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CAR | 2021 |
| 2021-10-29 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,526 | EX9536-4388 | 2021 |
| 2021-09-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,750 | EX9536-4388 | 2021 |
| 2021-09-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,750 | EX9536-4388 | 2021 |
| 2021-08-30 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $225 | EX9536-4388 | 2021 |
| 2021-07-28 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,420 | EX9536-4388 | 2021 |
| 2021-06-28 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $594 | EX9536-4388 | 2021 |
| 2021-04-26 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,120 | EX9536-4388 | 2021 |
| 2021-03-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $250 | EX9536-4388 | 2021 |
| 2021-03-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,291 | EX9536-4388 | 2021 |
| 2021-01-28 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,076 | EX9536-4388 | 2021 |
| 2021-01-28 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $200 | EX9536-4388 | 2021 |
| 2021-01-27 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $16,650 | MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEV | 2021 |
| 2021-01-15 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $23,094 | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2021 |
| 2020-12-22 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $594 | EX9536-4388 | 2020 |
| 2020-12-18 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $23 | EX9536-4388 | 2020 |
| 2020-11-30 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $594 | EX9536-4388 | 2020 |
| 2020-10-29 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,119 | EX9536-4388 | 2020 |
| 2020-09-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,295 | EX9536-4388 | 2020 |
| 2020-08-27 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,340 | EX9536-4388 | 2020 |
| 2020-08-25 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $19,425 | MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEV | 2020 |
| 2020-07-30 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $637 | EX9536-4388 | 2020 |
| 2020-06-23 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $3,242 | EX9536-4388 | 2020 |
| 2020-05-28 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,340 | EX9536-4388 | 2020 |
| 2020-04-30 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $75 | EX9536-4388 | 2020 |
| 2020-04-30 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,889 | EX9536-4388 | 2020 |
| 2020-03-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,853 | EX9536-4388 | 2020 |
| 2020-03-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $200 | EX9536-4388 | 2020 |
| 2020-02-27 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $648 | EX9536-4388 | 2020 |
| 2020-02-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $24 | EX9536-4388 | 2020 |
| 2020-01-28 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $4,349 | EX9536-4388 | 2020 |
| 2019-12-23 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,285 | EX9536-4388 | 2019 |
| 2019-12-06 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $24 | EX9536-4388 | 2019 |
| 2019-12-03 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $20,498 | NN2211-4232 | 2019 |
| 2019-12-03 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,680 | EX9536-4388 | 2019 |
| 2019-10-29 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,720 | EX9536-4388 | 2019 |
| 2019-09-26 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $5,213 | EX9536-4388 | 2019 |
| 2019-08-09 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $24 | EX9536-4388 | 2019 |
| 2019-07-30 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,460 | EX9536-4388 | 2019 |
| 2019-07-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $24 | EX9536-4388 | 2019 |
| 2019-06-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $648 | EX9536-4388 | 2019 |
| 2019-06-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,092 | NN2211-4232 | 2019 |
| 2019-05-28 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $691 | EX9536-4388 | 2019 |
| 2019-04-26 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $5 | NN2211-4232 | 2019 |
| 2019-04-25 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $648 | EX9536-4388 | 2019 |
| 2019-03-26 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $2,240 | EX9536-4388 | 2019 |
| 2019-03-26 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,770 | NN2211-4232 | 2019 |
| 2019-03-11 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $8,846 | A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ6 | 2019 |
| 2019-02-14 | Novartis Pharmaceuticals Corporation | BELZONI CLINICAL RESEARCH | $14,316 | A 52 WEEK OPEN LABEL EVALUATION OF THE EFFECTS OF SACUBITRIL VALSARTAN LCZ696 THERAPY ON BIOMARKERS MYOCARDIAL REMODELIN | 2019 |
| 2019-02-08 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1 | EX9536-4388 | 2019 |
| 2019-01-24 | Novo Nordisk AS | BELZONI CLINICAL RESEARCH | $1,092 | NN2211-4232 | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Belzoni, MS, county Humphreys County, MS, state Mississippi; placed by its city name.
| Measure | Place (city or town) Belzoni, MS | County Humphreys County, MS | State Mississippi |
|---|---|---|---|
| Population B01003 | 1,306 | 7,395 | 2,946,779 |
| Population, 2020 census P1 | 1,938 | 7,785 | 2,961,279 |
| Median age B01002 | 55.4 | 39.6 | 38.6 |
| Under 18 B01001 | 14.6% | 25.2% | 23.3% |
| 65 and over B01001 | 31.4% | 18.9% | 17.2% |
| Households B11001 | 646 | 2,900 | 1,145,431 |
| Foreign born B05002 | 1.1% | 0.4% | 2.4% |
| Median household income B19013 | $34,318 | $33,731 | $56,447 |
| Median family income B19113 | $67,794 | $40,034 | $73,163 |
| Per capita income B19301 | $27,489 | $23,712 | $31,549 |
| Poverty rate B17001 | 18.8% | 27.0% | 18.9% |
| Unemployment rate B23025 | 9.4% | 12.5% | 5.8% |
| Civilian labor force B23025 | 481 | 2,948 | 1,332,121 |
| Mean commute (minutes) B08013 | 19.6 | 22.4 | 25.6 |
| Bachelor's degree or higher B15003 | 24.7% | 19.6% | 25.1% |
| Housing units B25001 | 886 | 3,509 | 1,341,114 |
| Owner-occupied B25003 | 69.7% | 61.7% | 70.0% |
| Renters B25003 | 30.3% | 38.3% | 30.0% |
| Median home value B25077 | $109,600 | $87,800 | $169,800 |
| Median gross rent B25064 | $732 | $641 | $954 |
| White, not Hispanic B03002 | 18.8% | 20.2% | 55.2% |
| Black B03002 | 77.3% | 78.2% | 36.3% |
| Hispanic or Latino B03002 | 0.1% | 0.4% | 3.7% |
| Asian B03002 | 1.1% | 0.2% | 1.0% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.4% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Belzoni, MS.
Comments